Literature DB >> 26753750

Postoperative Infectious Complications are Associated with Adverse Oncologic Outcomes in Esophageal Cancer Patients Undergoing Preoperative Chemotherapy.

Kotaro Yamashita1, Tomoki Makino2, Hiroshi Miyata3, Yasuhiro Miyazaki1, Tsuyoshi Takahashi1, Yukinori Kurokawa1, Makoto Yamasaki1, Kiyokazu Nakajima1, Shuji Takiguchi1, Masaki Mori1, Yuichiro Doki1.   

Abstract

BACKGROUND: For some types of cancer, postoperative complications can negatively influence survival, but the association between these complications and oncological outcomes is unclear for patients with esophageal cancer who receive preoperative treatments.
METHODS: Data were retrospectively analyzed for patients who underwent curative resection following preoperative chemotherapy for esophageal squamous cell carcinoma from 2001 to 2011. Clinicopathological parameters and cancer-specific survival (CSS) were compared between patients with and without severe postoperative complications, grade III or higher, using the Clavien-Dindo classification.
RESULTS: Of 255 patients identified, 104 (40.8 %) postoperatively developed severe complications. The most common complication was atelectasis in 61 (23.9 %), followed by pulmonary infection in 22 (8.6 %). Three-field lymphadenectomy, longer operation time, and more blood loss were significantly associated with a higher incidence of severe complications. Multivariate analysis of CSS revealed severe complications [hazard ratio (HR) = 1.642, 95 % confidence interval (95 % CI) 1.095-2.460, p = 0.016] as a significant prognostic factor along with pT stage [HR = 2.081, 95 % CI 1.351-3.266, p < 0.001] and pN stage [HR = 3.724, 95 % CI 2.111-7.126, p < 0.001], whereas postoperative serum C-reactive protein value was not statistically significant. Among all complications, severe pulmonary infection was the only independent prognostic factor [HR = 2.504, 95 % CI 1.308-4.427, p = 0.007].
CONCLUSIONS: The incidence of postoperative infectious complications, in particular pulmonary infection, is associated with unfavorable prognosis in patients with esophageal cancer undergoing preoperative chemotherapy.

Entities:  

Mesh:

Year:  2016        PMID: 26753750     DOI: 10.1245/s10434-015-5045-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  23 in total

1.  Preoperative controlling nutritional status (CONUT) is useful to estimate the prognosis after esophagectomy for esophageal cancer.

Authors:  Naoya Yoshida; Kazuto Harada; Yoshifumi Baba; Keisuke Kosumi; Masaaki Iwatsuki; Koichi Kinoshita; Kenichi Nakamura; Yasuo Sakamoto; Yuji Miyamoto; Ryuichi Karashima; Kosuke Mima; Hiroshi Sawayama; Mayuko Ohuchi; Akira Chikamoto; Yu Imamura; Masayuki Watanabe; Hideo Baba
Journal:  Langenbecks Arch Surg       Date:  2017-01-30       Impact factor: 3.445

2.  Glycemic Status and Prognosis of Patients with Squamous Cell Carcinoma of the Esophagus.

Authors:  Akihiko Okamura; Masayuki Watanabe; Yu Imamura; Masaru Hayami; Kotaro Yamashita; Takanori Kurogochi; Shinji Mine
Journal:  World J Surg       Date:  2017-10       Impact factor: 3.352

3.  Inflammatory response and recurrence after minimally invasive esophagectomy.

Authors:  Akihiko Okamura; Kotaro Yamashita; Ryotaro Kozuki; Keita Takahashi; Tasuku Toihata; Yu Imamura; Shinji Mine; Masayuki Watanabe
Journal:  Langenbecks Arch Surg       Date:  2019-08-30       Impact factor: 3.445

4.  Actual Sarcopenia Reflects Poor Prognosis in Patients with Esophageal Cancer.

Authors:  Akihiro Watanabe; Taro Oshikiri; Ryuichiro Sawada; Hitoshi Harada; Naoki Urakawa; Hironobu Goto; Hiroshi Hasegawa; Shingo Kanaji; Kimihiro Yamashita; Takeru Matsuda; Daisuke Makiura; Yoshihiro Kakeji
Journal:  Ann Surg Oncol       Date:  2022-02-15       Impact factor: 5.344

5.  Clinical Impact of Platelet-to-albumin Ratio on Esophageal Cancer Patients Who Receive Curative Treatment.

Authors:  Toru Aoyama; Miwha Ju; Keisuke Komori; Hiroshi Tamagawa; Ayako Tamagawa; Junya Morita; Itaru Hashimoto; Tetsushi Ishiguro; Atsushi Onodera; Haruhiko Cho; Kazuya Endo; Shizune Onuma; Kazuki Kano; Kentaro Hara; Momoko Fukuda; Takashi Oshima; Norio Yukawa; Yasushi Rino
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

6.  Predictive model of postoperative pneumonia after neoadjuvant immunochemotherapy for esophageal cancer.

Authors:  Wei Wang; Yongkui Yu; Haibo Sun; Zongfei Wang; Yan Zheng; Guanghui Liang; Peinan Chen; Jiwei Cheng; Xiaoxia Xu; Funa Yang; Qi Liu; Weiqun Xing
Journal:  J Gastrointest Oncol       Date:  2022-04

7.  Impact of severe postoperative inflammatory response on recurrence after curative resection of colorectal cancer.

Authors:  Yuya Nakamura; Tadayoshi Yamaura; Yousuke Kinjo; Makoto Kawase; Satoshi Kanto; Nobukazu Kuroda
Journal:  Int J Colorectal Dis       Date:  2022-10-24       Impact factor: 2.796

8.  The survival impact of postoperative complications after curative resection in patients with esophageal squamous cell carcinoma: propensity score-matching analysis.

Authors:  Manabu Yamamoto; Mototsugu Shimokawa; Daisuke Yoshida; Shohei Yamaguchi; Mitsuhiko Ohta; Akinori Egashira; Masahiko Ikebe; Masaru Morita; Yasushi Toh
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-17       Impact factor: 4.553

9.  The impact of the Charlson comorbidity index on the prognosis of esophageal cancer patients who underwent esophagectomy with curative intent.

Authors:  Kotaro Yamashita; Masayuki Watanabe; Shinji Mine; Ian Fukudome; Akihiko Okamura; Masami Yuda; Masaru Hayami; Yu Imamura
Journal:  Surg Today       Date:  2018-01-30       Impact factor: 2.549

10.  Minimally invasive esophagectomy attenuates the postoperative inflammatory response and improves survival compared with open esophagectomy in patients with esophageal cancer: a propensity score matched analysis.

Authors:  Kotaro Yamashita; Masayuki Watanabe; Shinji Mine; Tasuku Toihata; Ian Fukudome; Akihiko Okamura; Masami Yuda; Masaru Hayami; Naoki Ishizuka; Yu Imamura
Journal:  Surg Endosc       Date:  2018-04-11       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.